JPS6357407B2 - - Google Patents
Info
- Publication number
- JPS6357407B2 JPS6357407B2 JP59223825A JP22382584A JPS6357407B2 JP S6357407 B2 JPS6357407 B2 JP S6357407B2 JP 59223825 A JP59223825 A JP 59223825A JP 22382584 A JP22382584 A JP 22382584A JP S6357407 B2 JPS6357407 B2 JP S6357407B2
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- activity
- antithrombotic agent
- active ingredient
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 31
- 229960002897 heparin Drugs 0.000 claims description 26
- 229920000669 heparin Polymers 0.000 claims description 26
- 239000003146 anticoagulant agent Substances 0.000 claims description 12
- 229960004676 antithrombotic agent Drugs 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 6
- 206010061216 Infarction Diseases 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 239000002565 heparin fraction Substances 0.000 claims description 3
- 230000035322 succinylation Effects 0.000 claims description 3
- 238000010613 succinylation reaction Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 206010008138 Cerebral venous thrombosis Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 11
- 230000001858 anti-Xa Effects 0.000 description 9
- 230000014508 negative regulation of coagulation Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 102000005686 Serum Globulins Human genes 0.000 description 7
- 108010045362 Serum Globulins Proteins 0.000 description 7
- 230000002785 anti-thrombosis Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010047249 Venous thrombosis Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000002628 heparin derivative Substances 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 231100000216 vascular lesion Toxicity 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- SYPCZULDXYOTGC-IVMDWMLBSA-N (3R,4R,5S,6R)-6-(hydroxymethyl)-3-(sulfonylamino)oxane-2,4,5-triol Chemical group S(=O)(=O)=N[C@H]1C(O)O[C@@H]([C@H]([C@@H]1O)O)CO SYPCZULDXYOTGC-IVMDWMLBSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- KZWHEHSUEBTKJM-SLPGGIOYSA-N [(2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl]sulfamic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NS(O)(=O)=O KZWHEHSUEBTKJM-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ãç£æ¥äžã®å©çšåéã
æ¬çºæã¯ä¿®é£Ÿã°ã«ã³ãµããã°ã«ã«ã³é¡ãæå¹æ
åãšããŠå«ãæè¡æ å€ã«é¢ããã ãåŸæ¥ã®æè¡ã è¡æ ã¯ç¶²ç¶ãã€ããªã³äžã§è¡å°æ¿ãšå€æ žçœè¡ç
ã®åéã§ãããå¿èæ¢å¡ïŒcardiac infarctïŒã
è³æ¢å¡ïŒcerefral infarctïŒãéèè¡æ ãšããŠç¥ã
ããé節ãªè¡ç®¡ç å€ãã²ããããéèŠãªèŠå ãšè
ããããŠããã è¡æ ã¯ãååºæ ãŸãã¯ååºå¡ãšãã°ããååºãš
ã¯æ§é çã«ç°ãªããã®ã§ããããšã匷調ããå¿ èŠ
ããããå®éãååºæ ãªã©ã¯è¡ç®¡ç å€ã®å Žæã«åœ¢
æãããã®ã«å¯ŸããŠãçã®è¡æ ã¯è¡æ¶²åŸªç°äžã«ã
圢æãããå¿ ãããè¡ç®¡ç å€ãã²ãããããã®ã§
ã¯ãªãããããã®åéãæ··åããããšãéååºæ§
ã«åºã¥ãååºç³»ã®åçŽãªå€èª¿ãè¡æ ã圢æãããš
ãã誀ãŸã€ã芳念ãç£ã¿åºããããããã®ç å€ã
äºç¥ã§ãããŸãåã«æååºå€ãæäžããããšã«ã
ãæ²»çã§ãããšä¿¡ããããŠãããããã«ãåèè¡
æ ãšéèè¡æ ãåºå¥ããå¿ èŠãããããšããã®
ã¯ãããåèã«è¡æ ã圢æããããšè¡æµã®éæ¢ã
ããããããã«äŒŽã€ãŠæ¢å¡ãããããäžæ¹ãéè
ã«è¡æ ã圢æããããšããããç Žãããèºã®ã¬ã
ã«ã§è¡æ ã倧ãããªã€ãŠå¡æ ãã§ãããããŠãã
ããæ»äº¡åå ãšãªãã è¡æ äºé²ã«ãããŠã¯è¡å°æ¿ã®æåé掻æ§ãæã
ãç©è³ªããã€ããªã³ãå¯æº¶æ§ããããã«å解ãã
ãã€ããªã³æº¶è§£å€ã網ç¶ãã€ããªã³ã圢æããã
ãã€ãã®å åã®é»å®³å€ãšããŠåãè¬å€ãªã©ã䜿çš
ãããŠããããããã®å åã®äžã§ã¯å åšæ§ååºå
ã®æ§ææåã§ããããã³ãã³ãšXaãã¢ã¯ã¿ãŒ
ïŒæŽ»æ§å åïŒãé瀺ãããŠããããã®ïŒã€ã®å
åã®é»å®³å€ãšããŠæãåºãçšããããŠãããã®ã®
ïŒã€ããããªã³ã§ããã ãã®è¬å€ã®æè¡æ 掻æ§ã¯æXa掻æ§ã倧ããã
ã°å€§ããã»ã©ãã®æè¡æ 掻æ§ã倧ãããªããšãã
æå³ã«ãããŠã¯ãæXa掻æ§ã§ãããšè¡šçŸããã
ãšãã§ãããå®éããããªã³è£œå€ã¯é«ãæååºæŽ»
æ§ãšãšãã«é«ãæXa掻æ§ãã瀺ããŠãããæå
åºæŽ»æ§ã¯äžè¬ã«åœéåäœïŒmgïŒIUïŒmgïŒã§è¡šã
ãããŠããããã®ãããªã³ã¯æäžããéšäœã«è¡è «
ã圢æãããããŸããã®è£œå€ã®é·æ䜿çšã§äœååº
èœãšããå±éºãªç¶æ ãã²ãããããããããšãã€
ãããããŠé節ãªå¯äœçšãæãããã ããã«çŸåšãŸã§ã«ãªãããèšåºç 究ã«å ±åãã
ãŠããããã«ãéèè¡æ ãäºé²ããããšãã§ããŠ
ãããã¯éèè¡æ ã«ã¯ããŠã¯ãŸããªããšããäºå®
ãç¥ãããŠããã ãçºæã解決ããããšããåé¡ç¹ã ãããããæååºæŽ»æ§ãæXa掻æ§ããã³ãã
çš®ã®ãã€ããªã³æº¶è§£æŽ»æ§ãæããªãããŸãã¯æ®ã
ã©æããªããããªè¬å€ã䜿çšããããšããéèè¡
æ ãåèè¡æ ãé²ãããã«ã¯éåžžã«æãŸãããã
ããã®çç±ãããé«ãæXa掻æ§ãšããå°ãªãæ
ååºæŽ»æ§ã瀺ããããªã³ãã©ã¯ã·ãšã³ïŒãããã¯
ãããªã³ããããããå šäœãšããŠã§ã¯ããŸããŸãª
æ§é ç°åããã³æãããªå€åæ£ç³»ã®ååéã瀺
ãïŒã®è£œæ³ãããã€ãŠäžçäžã§ç 究ããªãããŠã
ãïŒããšãã°HolwerE.ãâThrombos res.ïŒâ
25ïŒ475ïŒ1982ïŒïŒã æ¬çºæè ãã¯ãã€ã¿ãªã¢ç¹èš±åºé¡ç¬¬22851AïŒ
80å·æ现æžã«èšèŒãããŠãããããªã³èªå°äœãã
ãªãã¡ãããªã³ã®ïŒ®âè±ç¡«é žåãšããã«ã€ã¥ããµ
ã¯ã·ãã«åã®éçšããžãŠãããããããªã³èªå°äœ
ããé©ãã¹ãããšã«æ¥µããŠäœãããŸãã¯å šãæå
åºæŽ»æ§ã瀺ããããã€å°ãªãããŸãã¯å šãæXa
掻æ§ã瀺ãããåæç©è³ªã§ãããããªã³ã«é¢ãã
å åæºè¶³ã®ããèèªå解掻æ§ã«ã瀺ããŠãããã
ãã«çäœå ã§è¡æ ã®åœ¢æã«å¯ŸããŠææãªæå¶æŽ»æ§
ã瀺ãããšãèŠåºããæ¬çºæãå®æããã ãåé¡ç¹ã解決ããããã®æ段ã ããªãã¡æ¬çºæã¯ãâè±ç¡«é žããã³ãµã¯ã·ã
ã«åããããšã«ãã€ãŠä¿®é£ŸãããŠãããããªã³ã®
ãã©ã¯ã·ãšã³ã§ãã€ãŠã該ãã©ã¯ã·ãšã³ãâç¡«
é žåºã修食åã®ãããªã³ã®10ïŒ æªæºå«ã¿ãã€äºç³
åäœããã0.6ãè¶ ãããµã¯ã·ãã«åºãå«ãã§ã
ããããªã³ãã©ã¯ã·ãšã³ãæå¹æåãšããå¿èæ¢
å¡ãè³æ¢å¡ããã³éèè¡æ ã®äºé²ããã³æ²»çã«æ
çšãªæè¡æ å€ã«é¢ããã ãäœçšããã³å®æœäŸã ãã®ååç©æããæè¡æ 掻æ§ã¯ããã®åŒ·ãã«é¢
ããéãããã®ååç©ã瀺ããæååºæŽ»æ§ãšæ
Xa掻æ§ïŒãããã0.21UïŒmgããã³2UïŒmgïŒã®
å€ïŒãããã¯ïŒãŸãã¯æ®ãã©ïŒã«è¿ãïŒã®ã¿ã«åº
ããŠèª¬æããããšã¯ã§ããªãã åèšãããªã³èªå°äœã®ç€ºãè¡æ 圢æãé²ãåã
ã¯ãããŸã§ææãããŠãããããŸããããŸã§ã®æ
è¡ãšã¯ã¡ãã€ãæ¹æ³ã§ããã âè±ç¡«é žåããããããªã³ã®ãµã¯ã·ãã«èªå°
äœã¯ãã«ã»ã«ã»ãŠã¯ã©ãã®è¥¿ãã€ãç¹èš±ç¬¬
1201322å·æ现æžã«ãèšèŒãããŠãããããããª
ãããã®ç¹èš±ã«ã¯åãç©è³ªã®æèèªè¡ç掻æ§ã®ã¿
ãèšèŒãããŠããããã®æŽ»æ§ã¯äœãæååºæŽ»æ§ã
䌎ã€ãŠããã åèšè¡æ 圢æã®æå¶æŽ»æ§ã®ã»ãã«ãåèšãããª
ã³èªå°äœã¯ãã€ããªã³æº¶è§£æŽ»æ§ã瀺ããŠãããã
ãã«ã€ããŠã¯ä»¥äžã«ç€ºãã®ã©ããã§ã®çäœå ã«ã
ããF.D.P.ïŒãã€ããªã³æº¶è§£çæç©ïŒã®æž¬å®ããª
ã€ã°ãããªã³ã®æº¶è§£æéã®æž¬å®ãããã§ã®å®éšã«
ãã€ãŠç€ºãããŠãããæ¬çºæã®è£œå€ã®æå¹æåãš
ããŠçšããããŠããâè±ç¡«é žãµã¯ã·ãã«åã°ã«
ã³ãµããã°ã«ã«ã³èªå°äœã¯ã€ã¿ãªã¢ç¹èš±åºé¡ç¬¬
22851AïŒ80å·æ现æžã«èšèŒãããŠããåèšæ¹æ³
ã«ãã€ãŠãããããããã«è©³ããã¯ããããªã³ã
70âãã100âã®éã§ïŒæé以äžãå°ãªããšã0.1
èŠå®ä»¥äžããªãã¹ããªã0.5èŠå®ããã以äžã®åŒ·
é žãçšããŠå æ°Žå解ãããã®åŸPH7.0以äžã®ç¡æ°Ž
ã³ãã¯é žãå æ°Žå解ããããããªã³ãšã®ééæ¯ã
ïŒïŒïŒããïŒïŒïŒçšåºŠã«ãªãããã«å ããŠå æ°Žå
解ç£ç©ããµã¯ã·ãã«åããã æ¬çºæã®æå¹æåã§ããã°ãªã³ãµããã°ã«ã«ã³
èªå°äœã¯ãåæç©è³ªã§ãããããªã³ã«ååšãã
âç¡«é žåºãããšã®10ïŒ æªæºå«ã¿ããµã¯ã·ãã«åºã
äºç³åäœããã0.6ãè¶ ããŠãæãŸããã¯çŽ1.2å«
ãã§ããã ã€ãã«è£œé äŸããã³è¬çè©ŠéšäŸããããŠæ¬çºæ
ã®æè¡æ å€ã説æããã 補é äŸ ïŒã®ãã©ã¹ã³ã«å·åŽåšãšæ¹ææ£ããšãã€ãã
ãŸãäžæŽ»æ§é°å²æ°äžã§åå¿ãããããã«ããçŽ ã¬
ã¹ãå ¥ããå ¥å£ãèšããããã®ãã©ã¹ã³ã«ïŒã®
èžæºæ°Žãå ¥ãããããªã³ã®ãããªãŠã å¡©200ïœã
å ãããã€ãã§æ¹æããªãã宀枩ã§æº¶è§£ããïŒèŠ
å®å¡©é ž400c.c.ãå ãããããããéæãªæº¶æ¶²ãã
ãçŽ ã¬ã¹ã«ãã€ãŠè±æ°ãããã®ãŸãŸããçŽ ã¬ã¹äž
ã«ãããŠãã®æº¶æ¶²ã沞隰ãã湯济ã«é眮ããïŒæ
éåå¿ãããããã®æº¶æ¶²ãåå¿åŸå®€æž©ã«å·åŽãã
æ°·å·åŽäžã§å·ããæ°Žé žåãããªãŠã 飜å溶液ãæ·»
å ãPHã8.5ã«èª¿è£œãããã€ãã§æž©åºŠãïŒã10âã
PHãæ°Žé žåãããªãŠã ã§çŽïŒã«èª¿è£œããç¶æ ã§ç¡
æ°Žã³ãã¯é ž400ïœãäœåãã«åããŠå ãããç¡æ°Ž
ã³ãã¯é ž400ïœãå ãããããšPHã¯çŽ7.4ã7.5ã«
ãªã€ããããããå·ãã溶液ã30åéæ¹æããã€
ãã§95ïŒ ãšã¿ããŒã«ããã®ïŒåéå ãããçæã
ãæ²æŸ±ç©ã¯åãã¯æ²¹ç¶ã§ãããããã°ããæŸçœ®ã
ãããšã«ãã次第ã«åºåœ¢ç¶ãšãªã€ãããããåžåŒ
æ¿Ÿéãã颚也ããã€ãã§ãã®æ²æŸ±ç©ãïŒã®èžæº
æ°Žã«åã³æº¶è§£ããå ¬ç§°çŽ600ãã«ãã³ã«ãããªã
ã®éæåšã«ãããèžæºæ°ŽãçšããŠã³ãã¯é žãããª
ãŠã ããªããªããŸã§éæãããæåŸã«ãããã溶
液ãåçµä¹Ÿç¥ãããšãéç¶çµæ¶ã®ïŒ®âè±ç¡«é žãµã¯
ã·ãã«åã°ã«ã³ãµããã°ã«ã«ã³èªå°äœã200ïœã
ãããã ïŒ 13CâNMRã¹ãã¯ãã«åæïŒ ãžãªããµã³âD2Oäžã§25.2MHzã§æž¬å®ããå éš
æšæºãšããŠã¯ãžãªããµã³ïŒppm67.4ïŒãçšããã
ãŒã¿ã¯ppmã§è¡šç€ºãããå®éšæ¹æ³ã¯G.GattiãB.
CasuãG.K.Hamuããã³A.S.Perlinãã
Macromolewlcs12ïŒ1001ïŒ1979ïŒã«ç€ºããæ¹æ³ã
çšããã ããããã¹ãã¯ãã«ããããªã³ãããªãŠã å¡©ã®
ãããªã³ãšæ¯èŒãããšãããåãæ¡ä»¶ã§æž¬å®ãã
ãšã€ãã®ã·ã°ãã«ããã³ãããªã³ãšã®å·®ç°ããã
ããã (1) æ°ããã·ã°ãã«ã181.8ã«èªããããããã¯
ã³ãã¯é žæ®åºã®COO-ã«ãããã®ãšèããã
ãã (2) æ°ããã·ã°ãã«ã177ã«èªããããããã¯ã³
ãã¯é žæ®åºã®âCONHã«ãããã®ãšèããã
ãã (3) 176.7ã«èªããããã·ã°ãã«ã¯ã€ããã³é žæ®
åºã®âCOOHã«ãããã®ãšèããããããã¯
ãããªã³ã®ãã®ãšäžèŽããã (4) 102ã«èªããããå°ããªã·ã°ãã«ã¯å°éå«ãŸ
ããŠããã°ã«ã¯ãã³é žæ®åºã®C1ã«ãããã®ãš
èããããããããããªã³ã®ãã®ãšäžèŽããã (5) 100ã«èªããããã·ã°ãã«ã¯ã€ããã³é žæ®åº
ã®C1ã«ãããã®ãšèãããããããªã³ã®ãã®
ãšäžèŽããã (6) 95.3ã«èªããããæ°ããã·ã°ãã«ã¯ïŒ®âãµã¯
ã·ãã«âã°ã«ã³ãµãã³ã®ãŠãããäžã®C1ã«ã
ããã®ãšèãããããåæã«åºçºç©è³ªã®ãããª
ã³ããã€ã°ã«ã³ãµãã³ââç¡«é žæ®åºã®C1ã«
ãããã®ãšèãããã97.7ã®ã·ã°ãã«ã®æ¶å€±ã
èªããããã (7) 72ãã76ã®éã«æ°ããäžé£ã®ã·ã²ãã«ãèªã
ãããããããã¯ïŒ®âãµã¯ã·ãã«ã°ã«ã³ãµãã³
æ®åºã®C2ãšC4ããŸãã€ããã³é žæ®åºã®C2ã«ã
ããã®ãšèããããããããã®ã·ã°ãã«ã¯ãã
ãªã³ã®ã¹ãã¯ãã«ã§ã¯76ã«åäžã®åŒ·ãã·ã°ãã«
ãšããŠçŸãããã (8) 70ãš71ã«èªããããïŒã€ã®ã·ã°ãã«ã¯ïŒ®âãµ
ã¯ã·ãã«ã°ã«ã³ãµãã³æ®åºã®C3ãšC5ãã€ãã
ã³é žæ®åºã®C3ãšC5ã«ãããã®ãšèããããã
ãããã¯ãããªã³ã®åãååã®ã·ã°ãã«ãšäžèŽ
ããã (9) 67ã«èªããããã·ã°ãã«ã¯ïŒ®âãµã¯ã·ãã«ã°
ã«ã³ãµãã³æ®åºã®C6ã«ãããã®ãšèããããã
ããã¯ãããªã³ã®ïŒ®âã¹ã«ããã«æ®åºã®C6ã®
ã·ã°ãã«ãšäžèŽããã (10) 54.5ã«èªããããæ°ããã·ã°ãã«ã¯ïŒ®âãµã¯
ã·ãã«ã°ã«ã³ãµãã³æ®åºã®C2ã«ãããã®ãšè
ãããããåæã«ãããªã³ã®ã¹ãã¯ãã«ã§èŠã
ããâã¹ã«ããã«ã°ã«ã³ãµãã³æ®åºã®C2ã«
ãã58.8ã®ã·ã°ãã«ãæ¶å€±ããã (11) 33.0ãš33.5ã«èªããããïŒã€ã®æ°ããã·ã°ã
ã«ã¯ãâãµã¯ã·ãã«ãããªã³äžã®ã³ãã¯é žæ®
åºã®âCH2COO-ãšâCH2âCOâNHâã«ãã
ãã®ãšèããããã è¬çè©Šéš ïŒæè¡æ 掻æ§ïŒ (1) 掻æ§ã®æ±ºå® å®éšã¯UmctzoïŒTeruhiro Umetzoã
âThrombâosis and HaemostasisâStuttgâ
39ã74ïŒ1978ïŒïŒã®æ¹æ³ãšããŠç¥ãããŠããæ¹æ³ã«
åŸã€ãŠè¡ãªã€ãããã®æ¹æ³ã¯ã©ããã®å³ã®ããå
èãšå·Šã®ããéèãã·ãªã³ãŒã³ããŠãŒãã§æ¥ç¶
ãããã®äžã«å·»ããã·ã«ã¯ã®ç³žã§ãããšã·ã³ã³ã®
糞ãå ¥ããŠããæ¹æ³ã§ãããããªãã¡ãããŠãŒã
ã§ã€ãªãã ããã«è¡æµã¯ããŠãŒããééãããã®
çµæ糞ã®ãŸããã«è¡æ ã圢æãããããããŠãã
ã¯æè¡æ å€ã®éååšäžã§ã¯ãã®è¡æ ééãéãã
æè¡æ å€ãååšããã°ããã«ã¯ãã®æŽ»æ§ãšçšéã«
ãããè¡æ ééã¯æžå°ããããæ¶å€±ããã å¯Ÿç §è¬ãšããŠãããªã³ïŒå éšæšæºïŒæååºæŽ»æ§
155IUïŒmgãæXa掻æ§168UïŒmgã§ããããã¯æ¯
è²å®éåšHepachromÃStagoâDiagnostic
Stagoãããªããã©ã³ã¹ã«ãã決å®ããïŒãçšã
ãã éšåçã«ïŒ®âè±ç¡«é žåããããµã¯ã·ãã«ã°ã«ã³
ãµããã°ã«ã«ã³ã®ãããªãŠã å¡©ïŒä»¥äžãGGMãš
ç¥ãïŒã®æååºæŽ»æ§ã¯0.2IUïŒmgãæXa掻æ§ã¯
2UïŒmgã§ãã€ãããããã®å€ã¯ãããªã³ãšåæ§
ã®æ¹æ³ãçšããŠæ±ºå®ããããããã«ã€ããŠã¯åºçº
ç©è³ªãšããŠåããããªã³ãçšããŠããã€ã¿ãªã¢ç¹
èš±åºé¡ç¬¬22851AïŒ80å·æ现æžã«èšèŒãããŠããã
å®éšã«ã¯äœéçŽ350ïœã®éæ§ã¢ã«ããã»ãŠã€ã¹ã¿
ãŒç³»ã©ãããçšãããŠã¬ã¿ã³ïŒ1.25ïœïŒKgãipïŒ
麻é äžã§è¡ãªã€ããäœå€è¡æ¶²åŸªç°ã«äŸããææã¯
å åŸ2.5mmãééïŒmgã®ãšã·ã³ã³ã§ãã€ãã 被æ€ç©è³ªã¯äœå€è¡æ¶²åŸªç°ãå§ããçŽåã«ççé£
å¡©æ°Žã«æº¶è§£ããŠïŒmgïŒKgã®å²åã§ã·ãªã³ãŒã³ããŠ
ãŒããéããŠæ³šå ¥ãããäœå€è¡æ¶²åŸªç°ã®æéã¯15
åéãšãããè¡æ ã¯ã·ãªã³ãŒã³ããŠãŒãããã·ã«
ã¯ã®ç³žãã²ãæããçŽã¡ã«ãã®ééã枬å®ããã
è¡æ ã®æ£ç¢ºãªééã¯å šééãã糞ã®ééãå·®ãåŒ
ããŠæ±ºå®ããã åç©ã®äžçŸ€ã¯ãè¡æ æå¶ç©è³ªããªãã°ããã®è¡
æ ééã®å¹³åå€ãããããã«ãççé£å¡©æ°Žã®ã¿ã
ïŒmlïŒKgã®å²åã§æäžãããããããã®åŠçåç©
ã«ã€ããŠãååºç³»ã«å¯ŸããåŠçã®åœ±é¿ã調ã¹ãã
ãã«ååºæéã枬å®ãããããããçµæã第ïŒè¡š
ã«ç€ºãã
åãšããŠå«ãæè¡æ å€ã«é¢ããã ãåŸæ¥ã®æè¡ã è¡æ ã¯ç¶²ç¶ãã€ããªã³äžã§è¡å°æ¿ãšå€æ žçœè¡ç
ã®åéã§ãããå¿èæ¢å¡ïŒcardiac infarctïŒã
è³æ¢å¡ïŒcerefral infarctïŒãéèè¡æ ãšããŠç¥ã
ããé節ãªè¡ç®¡ç å€ãã²ããããéèŠãªèŠå ãšè
ããããŠããã è¡æ ã¯ãååºæ ãŸãã¯ååºå¡ãšãã°ããååºãš
ã¯æ§é çã«ç°ãªããã®ã§ããããšã匷調ããå¿ èŠ
ããããå®éãååºæ ãªã©ã¯è¡ç®¡ç å€ã®å Žæã«åœ¢
æãããã®ã«å¯ŸããŠãçã®è¡æ ã¯è¡æ¶²åŸªç°äžã«ã
圢æãããå¿ ãããè¡ç®¡ç å€ãã²ãããããã®ã§
ã¯ãªãããããã®åéãæ··åããããšãéååºæ§
ã«åºã¥ãååºç³»ã®åçŽãªå€èª¿ãè¡æ ã圢æãããš
ãã誀ãŸã€ã芳念ãç£ã¿åºããããããã®ç å€ã
äºç¥ã§ãããŸãåã«æååºå€ãæäžããããšã«ã
ãæ²»çã§ãããšä¿¡ããããŠãããããã«ãåèè¡
æ ãšéèè¡æ ãåºå¥ããå¿ èŠãããããšããã®
ã¯ãããåèã«è¡æ ã圢æããããšè¡æµã®éæ¢ã
ããããããã«äŒŽã€ãŠæ¢å¡ãããããäžæ¹ãéè
ã«è¡æ ã圢æããããšããããç Žãããèºã®ã¬ã
ã«ã§è¡æ ã倧ãããªã€ãŠå¡æ ãã§ãããããŠãã
ããæ»äº¡åå ãšãªãã è¡æ äºé²ã«ãããŠã¯è¡å°æ¿ã®æåé掻æ§ãæã
ãç©è³ªããã€ããªã³ãå¯æº¶æ§ããããã«å解ãã
ãã€ããªã³æº¶è§£å€ã網ç¶ãã€ããªã³ã圢æããã
ãã€ãã®å åã®é»å®³å€ãšããŠåãè¬å€ãªã©ã䜿çš
ãããŠããããããã®å åã®äžã§ã¯å åšæ§ååºå
ã®æ§ææåã§ããããã³ãã³ãšXaãã¢ã¯ã¿ãŒ
ïŒæŽ»æ§å åïŒãé瀺ãããŠããããã®ïŒã€ã®å
åã®é»å®³å€ãšããŠæãåºãçšããããŠãããã®ã®
ïŒã€ããããªã³ã§ããã ãã®è¬å€ã®æè¡æ 掻æ§ã¯æXa掻æ§ã倧ããã
ã°å€§ããã»ã©ãã®æè¡æ 掻æ§ã倧ãããªããšãã
æå³ã«ãããŠã¯ãæXa掻æ§ã§ãããšè¡šçŸããã
ãšãã§ãããå®éããããªã³è£œå€ã¯é«ãæååºæŽ»
æ§ãšãšãã«é«ãæXa掻æ§ãã瀺ããŠãããæå
åºæŽ»æ§ã¯äžè¬ã«åœéåäœïŒmgïŒIUïŒmgïŒã§è¡šã
ãããŠããããã®ãããªã³ã¯æäžããéšäœã«è¡è «
ã圢æãããããŸããã®è£œå€ã®é·æ䜿çšã§äœååº
èœãšããå±éºãªç¶æ ãã²ãããããããããšãã€
ãããããŠé節ãªå¯äœçšãæãããã ããã«çŸåšãŸã§ã«ãªãããèšåºç 究ã«å ±åãã
ãŠããããã«ãéèè¡æ ãäºé²ããããšãã§ããŠ
ãããã¯éèè¡æ ã«ã¯ããŠã¯ãŸããªããšããäºå®
ãç¥ãããŠããã ãçºæã解決ããããšããåé¡ç¹ã ãããããæååºæŽ»æ§ãæXa掻æ§ããã³ãã
çš®ã®ãã€ããªã³æº¶è§£æŽ»æ§ãæããªãããŸãã¯æ®ã
ã©æããªããããªè¬å€ã䜿çšããããšããéèè¡
æ ãåèè¡æ ãé²ãããã«ã¯éåžžã«æãŸãããã
ããã®çç±ãããé«ãæXa掻æ§ãšããå°ãªãæ
ååºæŽ»æ§ã瀺ããããªã³ãã©ã¯ã·ãšã³ïŒãããã¯
ãããªã³ããããããå šäœãšããŠã§ã¯ããŸããŸãª
æ§é ç°åããã³æãããªå€åæ£ç³»ã®ååéã瀺
ãïŒã®è£œæ³ãããã€ãŠäžçäžã§ç 究ããªãããŠã
ãïŒããšãã°HolwerE.ãâThrombos res.ïŒâ
25ïŒ475ïŒ1982ïŒïŒã æ¬çºæè ãã¯ãã€ã¿ãªã¢ç¹èš±åºé¡ç¬¬22851AïŒ
80å·æ现æžã«èšèŒãããŠãããããªã³èªå°äœãã
ãªãã¡ãããªã³ã®ïŒ®âè±ç¡«é žåãšããã«ã€ã¥ããµ
ã¯ã·ãã«åã®éçšããžãŠãããããããªã³èªå°äœ
ããé©ãã¹ãããšã«æ¥µããŠäœãããŸãã¯å šãæå
åºæŽ»æ§ã瀺ããããã€å°ãªãããŸãã¯å šãæXa
掻æ§ã瀺ãããåæç©è³ªã§ãããããªã³ã«é¢ãã
å åæºè¶³ã®ããèèªå解掻æ§ã«ã瀺ããŠãããã
ãã«çäœå ã§è¡æ ã®åœ¢æã«å¯ŸããŠææãªæå¶æŽ»æ§
ã瀺ãããšãèŠåºããæ¬çºæãå®æããã ãåé¡ç¹ã解決ããããã®æ段ã ããªãã¡æ¬çºæã¯ãâè±ç¡«é žããã³ãµã¯ã·ã
ã«åããããšã«ãã€ãŠä¿®é£ŸãããŠãããããªã³ã®
ãã©ã¯ã·ãšã³ã§ãã€ãŠã該ãã©ã¯ã·ãšã³ãâç¡«
é žåºã修食åã®ãããªã³ã®10ïŒ æªæºå«ã¿ãã€äºç³
åäœããã0.6ãè¶ ãããµã¯ã·ãã«åºãå«ãã§ã
ããããªã³ãã©ã¯ã·ãšã³ãæå¹æåãšããå¿èæ¢
å¡ãè³æ¢å¡ããã³éèè¡æ ã®äºé²ããã³æ²»çã«æ
çšãªæè¡æ å€ã«é¢ããã ãäœçšããã³å®æœäŸã ãã®ååç©æããæè¡æ 掻æ§ã¯ããã®åŒ·ãã«é¢
ããéãããã®ååç©ã瀺ããæååºæŽ»æ§ãšæ
Xa掻æ§ïŒãããã0.21UïŒmgããã³2UïŒmgïŒã®
å€ïŒãããã¯ïŒãŸãã¯æ®ãã©ïŒã«è¿ãïŒã®ã¿ã«åº
ããŠèª¬æããããšã¯ã§ããªãã åèšãããªã³èªå°äœã®ç€ºãè¡æ 圢æãé²ãåã
ã¯ãããŸã§ææãããŠãããããŸããããŸã§ã®æ
è¡ãšã¯ã¡ãã€ãæ¹æ³ã§ããã âè±ç¡«é žåããããããªã³ã®ãµã¯ã·ãã«èªå°
äœã¯ãã«ã»ã«ã»ãŠã¯ã©ãã®è¥¿ãã€ãç¹èš±ç¬¬
1201322å·æ现æžã«ãèšèŒãããŠãããããããª
ãããã®ç¹èš±ã«ã¯åãç©è³ªã®æèèªè¡ç掻æ§ã®ã¿
ãèšèŒãããŠããããã®æŽ»æ§ã¯äœãæååºæŽ»æ§ã
䌎ã€ãŠããã åèšè¡æ 圢æã®æå¶æŽ»æ§ã®ã»ãã«ãåèšãããª
ã³èªå°äœã¯ãã€ããªã³æº¶è§£æŽ»æ§ã瀺ããŠãããã
ãã«ã€ããŠã¯ä»¥äžã«ç€ºãã®ã©ããã§ã®çäœå ã«ã
ããF.D.P.ïŒãã€ããªã³æº¶è§£çæç©ïŒã®æž¬å®ããª
ã€ã°ãããªã³ã®æº¶è§£æéã®æž¬å®ãããã§ã®å®éšã«
ãã€ãŠç€ºãããŠãããæ¬çºæã®è£œå€ã®æå¹æåãš
ããŠçšããããŠããâè±ç¡«é žãµã¯ã·ãã«åã°ã«
ã³ãµããã°ã«ã«ã³èªå°äœã¯ã€ã¿ãªã¢ç¹èš±åºé¡ç¬¬
22851AïŒ80å·æ现æžã«èšèŒãããŠããåèšæ¹æ³
ã«ãã€ãŠãããããããã«è©³ããã¯ããããªã³ã
70âãã100âã®éã§ïŒæé以äžãå°ãªããšã0.1
èŠå®ä»¥äžããªãã¹ããªã0.5èŠå®ããã以äžã®åŒ·
é žãçšããŠå æ°Žå解ãããã®åŸPH7.0以äžã®ç¡æ°Ž
ã³ãã¯é žãå æ°Žå解ããããããªã³ãšã®ééæ¯ã
ïŒïŒïŒããïŒïŒïŒçšåºŠã«ãªãããã«å ããŠå æ°Žå
解ç£ç©ããµã¯ã·ãã«åããã æ¬çºæã®æå¹æåã§ããã°ãªã³ãµããã°ã«ã«ã³
èªå°äœã¯ãåæç©è³ªã§ãããããªã³ã«ååšãã
âç¡«é žåºãããšã®10ïŒ æªæºå«ã¿ããµã¯ã·ãã«åºã
äºç³åäœããã0.6ãè¶ ããŠãæãŸããã¯çŽ1.2å«
ãã§ããã ã€ãã«è£œé äŸããã³è¬çè©ŠéšäŸããããŠæ¬çºæ
ã®æè¡æ å€ã説æããã 補é äŸ ïŒã®ãã©ã¹ã³ã«å·åŽåšãšæ¹ææ£ããšãã€ãã
ãŸãäžæŽ»æ§é°å²æ°äžã§åå¿ãããããã«ããçŽ ã¬
ã¹ãå ¥ããå ¥å£ãèšããããã®ãã©ã¹ã³ã«ïŒã®
èžæºæ°Žãå ¥ãããããªã³ã®ãããªãŠã å¡©200ïœã
å ãããã€ãã§æ¹æããªãã宀枩ã§æº¶è§£ããïŒèŠ
å®å¡©é ž400c.c.ãå ãããããããéæãªæº¶æ¶²ãã
ãçŽ ã¬ã¹ã«ãã€ãŠè±æ°ãããã®ãŸãŸããçŽ ã¬ã¹äž
ã«ãããŠãã®æº¶æ¶²ã沞隰ãã湯济ã«é眮ããïŒæ
éåå¿ãããããã®æº¶æ¶²ãåå¿åŸå®€æž©ã«å·åŽãã
æ°·å·åŽäžã§å·ããæ°Žé žåãããªãŠã 飜å溶液ãæ·»
å ãPHã8.5ã«èª¿è£œãããã€ãã§æž©åºŠãïŒã10âã
PHãæ°Žé žåãããªãŠã ã§çŽïŒã«èª¿è£œããç¶æ ã§ç¡
æ°Žã³ãã¯é ž400ïœãäœåãã«åããŠå ãããç¡æ°Ž
ã³ãã¯é ž400ïœãå ãããããšPHã¯çŽ7.4ã7.5ã«
ãªã€ããããããå·ãã溶液ã30åéæ¹æããã€
ãã§95ïŒ ãšã¿ããŒã«ããã®ïŒåéå ãããçæã
ãæ²æŸ±ç©ã¯åãã¯æ²¹ç¶ã§ãããããã°ããæŸçœ®ã
ãããšã«ãã次第ã«åºåœ¢ç¶ãšãªã€ãããããåžåŒ
æ¿Ÿéãã颚也ããã€ãã§ãã®æ²æŸ±ç©ãïŒã®èžæº
æ°Žã«åã³æº¶è§£ããå ¬ç§°çŽ600ãã«ãã³ã«ãããªã
ã®éæåšã«ãããèžæºæ°ŽãçšããŠã³ãã¯é žãããª
ãŠã ããªããªããŸã§éæãããæåŸã«ãããã溶
液ãåçµä¹Ÿç¥ãããšãéç¶çµæ¶ã®ïŒ®âè±ç¡«é žãµã¯
ã·ãã«åã°ã«ã³ãµããã°ã«ã«ã³èªå°äœã200ïœã
ãããã ïŒ 13CâNMRã¹ãã¯ãã«åæïŒ ãžãªããµã³âD2Oäžã§25.2MHzã§æž¬å®ããå éš
æšæºãšããŠã¯ãžãªããµã³ïŒppm67.4ïŒãçšããã
ãŒã¿ã¯ppmã§è¡šç€ºãããå®éšæ¹æ³ã¯G.GattiãB.
CasuãG.K.Hamuããã³A.S.Perlinãã
Macromolewlcs12ïŒ1001ïŒ1979ïŒã«ç€ºããæ¹æ³ã
çšããã ããããã¹ãã¯ãã«ããããªã³ãããªãŠã å¡©ã®
ãããªã³ãšæ¯èŒãããšãããåãæ¡ä»¶ã§æž¬å®ãã
ãšã€ãã®ã·ã°ãã«ããã³ãããªã³ãšã®å·®ç°ããã
ããã (1) æ°ããã·ã°ãã«ã181.8ã«èªããããããã¯
ã³ãã¯é žæ®åºã®COO-ã«ãããã®ãšèããã
ãã (2) æ°ããã·ã°ãã«ã177ã«èªããããããã¯ã³
ãã¯é žæ®åºã®âCONHã«ãããã®ãšèããã
ãã (3) 176.7ã«èªããããã·ã°ãã«ã¯ã€ããã³é žæ®
åºã®âCOOHã«ãããã®ãšèããããããã¯
ãããªã³ã®ãã®ãšäžèŽããã (4) 102ã«èªããããå°ããªã·ã°ãã«ã¯å°éå«ãŸ
ããŠããã°ã«ã¯ãã³é žæ®åºã®C1ã«ãããã®ãš
èããããããããããªã³ã®ãã®ãšäžèŽããã (5) 100ã«èªããããã·ã°ãã«ã¯ã€ããã³é žæ®åº
ã®C1ã«ãããã®ãšèãããããããªã³ã®ãã®
ãšäžèŽããã (6) 95.3ã«èªããããæ°ããã·ã°ãã«ã¯ïŒ®âãµã¯
ã·ãã«âã°ã«ã³ãµãã³ã®ãŠãããäžã®C1ã«ã
ããã®ãšèãããããåæã«åºçºç©è³ªã®ãããª
ã³ããã€ã°ã«ã³ãµãã³ââç¡«é žæ®åºã®C1ã«
ãããã®ãšèãããã97.7ã®ã·ã°ãã«ã®æ¶å€±ã
èªããããã (7) 72ãã76ã®éã«æ°ããäžé£ã®ã·ã²ãã«ãèªã
ãããããããã¯ïŒ®âãµã¯ã·ãã«ã°ã«ã³ãµãã³
æ®åºã®C2ãšC4ããŸãã€ããã³é žæ®åºã®C2ã«ã
ããã®ãšèããããããããã®ã·ã°ãã«ã¯ãã
ãªã³ã®ã¹ãã¯ãã«ã§ã¯76ã«åäžã®åŒ·ãã·ã°ãã«
ãšããŠçŸãããã (8) 70ãš71ã«èªããããïŒã€ã®ã·ã°ãã«ã¯ïŒ®âãµ
ã¯ã·ãã«ã°ã«ã³ãµãã³æ®åºã®C3ãšC5ãã€ãã
ã³é žæ®åºã®C3ãšC5ã«ãããã®ãšèããããã
ãããã¯ãããªã³ã®åãååã®ã·ã°ãã«ãšäžèŽ
ããã (9) 67ã«èªããããã·ã°ãã«ã¯ïŒ®âãµã¯ã·ãã«ã°
ã«ã³ãµãã³æ®åºã®C6ã«ãããã®ãšèããããã
ããã¯ãããªã³ã®ïŒ®âã¹ã«ããã«æ®åºã®C6ã®
ã·ã°ãã«ãšäžèŽããã (10) 54.5ã«èªããããæ°ããã·ã°ãã«ã¯ïŒ®âãµã¯
ã·ãã«ã°ã«ã³ãµãã³æ®åºã®C2ã«ãããã®ãšè
ãããããåæã«ãããªã³ã®ã¹ãã¯ãã«ã§èŠã
ããâã¹ã«ããã«ã°ã«ã³ãµãã³æ®åºã®C2ã«
ãã58.8ã®ã·ã°ãã«ãæ¶å€±ããã (11) 33.0ãš33.5ã«èªããããïŒã€ã®æ°ããã·ã°ã
ã«ã¯ãâãµã¯ã·ãã«ãããªã³äžã®ã³ãã¯é žæ®
åºã®âCH2COO-ãšâCH2âCOâNHâã«ãã
ãã®ãšèããããã è¬çè©Šéš ïŒæè¡æ 掻æ§ïŒ (1) 掻æ§ã®æ±ºå® å®éšã¯UmctzoïŒTeruhiro Umetzoã
âThrombâosis and HaemostasisâStuttgâ
39ã74ïŒ1978ïŒïŒã®æ¹æ³ãšããŠç¥ãããŠããæ¹æ³ã«
åŸã€ãŠè¡ãªã€ãããã®æ¹æ³ã¯ã©ããã®å³ã®ããå
èãšå·Šã®ããéèãã·ãªã³ãŒã³ããŠãŒãã§æ¥ç¶
ãããã®äžã«å·»ããã·ã«ã¯ã®ç³žã§ãããšã·ã³ã³ã®
糞ãå ¥ããŠããæ¹æ³ã§ãããããªãã¡ãããŠãŒã
ã§ã€ãªãã ããã«è¡æµã¯ããŠãŒããééãããã®
çµæ糞ã®ãŸããã«è¡æ ã圢æãããããããŠãã
ã¯æè¡æ å€ã®éååšäžã§ã¯ãã®è¡æ ééãéãã
æè¡æ å€ãååšããã°ããã«ã¯ãã®æŽ»æ§ãšçšéã«
ãããè¡æ ééã¯æžå°ããããæ¶å€±ããã å¯Ÿç §è¬ãšããŠãããªã³ïŒå éšæšæºïŒæååºæŽ»æ§
155IUïŒmgãæXa掻æ§168UïŒmgã§ããããã¯æ¯
è²å®éåšHepachromÃStagoâDiagnostic
Stagoãããªããã©ã³ã¹ã«ãã決å®ããïŒãçšã
ãã éšåçã«ïŒ®âè±ç¡«é žåããããµã¯ã·ãã«ã°ã«ã³
ãµããã°ã«ã«ã³ã®ãããªãŠã å¡©ïŒä»¥äžãGGMãš
ç¥ãïŒã®æååºæŽ»æ§ã¯0.2IUïŒmgãæXa掻æ§ã¯
2UïŒmgã§ãã€ãããããã®å€ã¯ãããªã³ãšåæ§
ã®æ¹æ³ãçšããŠæ±ºå®ããããããã«ã€ããŠã¯åºçº
ç©è³ªãšããŠåããããªã³ãçšããŠããã€ã¿ãªã¢ç¹
èš±åºé¡ç¬¬22851AïŒ80å·æ现æžã«èšèŒãããŠããã
å®éšã«ã¯äœéçŽ350ïœã®éæ§ã¢ã«ããã»ãŠã€ã¹ã¿
ãŒç³»ã©ãããçšãããŠã¬ã¿ã³ïŒ1.25ïœïŒKgãipïŒ
麻é äžã§è¡ãªã€ããäœå€è¡æ¶²åŸªç°ã«äŸããææã¯
å åŸ2.5mmãééïŒmgã®ãšã·ã³ã³ã§ãã€ãã 被æ€ç©è³ªã¯äœå€è¡æ¶²åŸªç°ãå§ããçŽåã«ççé£
å¡©æ°Žã«æº¶è§£ããŠïŒmgïŒKgã®å²åã§ã·ãªã³ãŒã³ããŠ
ãŒããéããŠæ³šå ¥ãããäœå€è¡æ¶²åŸªç°ã®æéã¯15
åéãšãããè¡æ ã¯ã·ãªã³ãŒã³ããŠãŒãããã·ã«
ã¯ã®ç³žãã²ãæããçŽã¡ã«ãã®ééã枬å®ããã
è¡æ ã®æ£ç¢ºãªééã¯å šééãã糞ã®ééãå·®ãåŒ
ããŠæ±ºå®ããã åç©ã®äžçŸ€ã¯ãè¡æ æå¶ç©è³ªããªãã°ããã®è¡
æ ééã®å¹³åå€ãããããã«ãççé£å¡©æ°Žã®ã¿ã
ïŒmlïŒKgã®å²åã§æäžãããããããã®åŠçåç©
ã«ã€ããŠãååºç³»ã«å¯ŸããåŠçã®åœ±é¿ã調ã¹ãã
ãã«ååºæéã枬å®ãããããããçµæã第ïŒè¡š
ã«ç€ºãã
ãè¡šã
ãªããè¡æ 圢æã®æå¶çã¯ççé£å¡©æ°Žã®ã¿ãæ
äžãã矀ã®è¡æ ééãšæ¯èŒããã°ããã®è¡æ éé
ã®æžå°éã«æç®ããŠèšç®ãããççé£å¡©æ°Žã®ã¿ã«
æäžããã°ããã«ããããè¡æ ééã®å¹³åå€ã¯30
å¹ã®å¹³åã«ãããšã101.93±6.38mgã§ãã€ãã ååºãããŸã§ã®æéïŒççé£å¡©æ°Žãæäžããã°
ããã®ååºã«èŠããæéã¯ãå¹³å144.14±6.21ç§
ã§ãã€ãããããªã³ãæäžãããšãã®æéã¯çšé
äŸåçã«å€åããïŒmgïŒKgã®çšéã§ã¯521.40±
41.06ç§ã«ãŸã§éãããããããªããGCMã200
mgïŒKgã®çšéãŸã§æäžããŠãæéã¯ççé£å¡©æ°Žæ
äžæã®æéãå€ããããªãã400mgïŒKgãŸã§æäž
ããŠ228.50±17.55ç§ãšãªã€ãã ãããã®çµæã¯ãæããã«GGMã®æè¡æ 掻æ§
ãæããã³ãã³ã掻æ§åããããšã«ããæååºæŽ»
æ§ãçŸãããŠããã®ã§ã¯ãªããšããããšã瀺ããŠ
ãããããã«æXa掻æ§ã«ããå€ãäœãç¹ããè
ãããšãGGMã®æè¡æ 掻æ§ã¯Xaãã¢ã¯ã¿ãŒã®çŽ
æ¥çãªæå¶æŽ»æ§ã«ãããã®ã§ã¯ãªãã (2) 掻æ§ã®æ¥ç¶æé åèšãšåäžã®å®éšæ¡ä»¶äžã§ïŒçŸ€ïŒå¹ã®ã©ããã«
å®éšéå§æã«ãããªã³ã77.5IUïŒKgã®çšéã§æäž
ããGGMã115mgïŒKgã®çšéã§æäžããããã
ãã®çšéã¯æè¡æ 掻æ§ã«ãããŠåã掻æ§ããã€çš
éã§ãããããã«ç¬¬ïŒè¡šã«ç€ºãããã«è¢«æ€ç©è³ªã®
æäžãšäœå€è¡æ¶²åŸªç°ã®éå§ãŸã§ã®æéãããŸããŸ
ã«å€ããŠå®éšãè¡ãªã€ããçµæã第ïŒè¡šã«ç€ºãã
ããŒã¿ã¯åæéã§ããããæå¶çã§ç€ºããã
äžãã矀ã®è¡æ ééãšæ¯èŒããã°ããã®è¡æ éé
ã®æžå°éã«æç®ããŠèšç®ãããççé£å¡©æ°Žã®ã¿ã«
æäžããã°ããã«ããããè¡æ ééã®å¹³åå€ã¯30
å¹ã®å¹³åã«ãããšã101.93±6.38mgã§ãã€ãã ååºãããŸã§ã®æéïŒççé£å¡©æ°Žãæäžããã°
ããã®ååºã«èŠããæéã¯ãå¹³å144.14±6.21ç§
ã§ãã€ãããããªã³ãæäžãããšãã®æéã¯çšé
äŸåçã«å€åããïŒmgïŒKgã®çšéã§ã¯521.40±
41.06ç§ã«ãŸã§éãããããããªããGCMã200
mgïŒKgã®çšéãŸã§æäžããŠãæéã¯ççé£å¡©æ°Žæ
äžæã®æéãå€ããããªãã400mgïŒKgãŸã§æäž
ããŠ228.50±17.55ç§ãšãªã€ãã ãããã®çµæã¯ãæããã«GGMã®æè¡æ 掻æ§
ãæããã³ãã³ã掻æ§åããããšã«ããæååºæŽ»
æ§ãçŸãããŠããã®ã§ã¯ãªããšããããšã瀺ããŠ
ãããããã«æXa掻æ§ã«ããå€ãäœãç¹ããè
ãããšãGGMã®æè¡æ 掻æ§ã¯Xaãã¢ã¯ã¿ãŒã®çŽ
æ¥çãªæå¶æŽ»æ§ã«ãããã®ã§ã¯ãªãã (2) 掻æ§ã®æ¥ç¶æé åèšãšåäžã®å®éšæ¡ä»¶äžã§ïŒçŸ€ïŒå¹ã®ã©ããã«
å®éšéå§æã«ãããªã³ã77.5IUïŒKgã®çšéã§æäž
ããGGMã115mgïŒKgã®çšéã§æäžããããã
ãã®çšéã¯æè¡æ 掻æ§ã«ãããŠåã掻æ§ããã€çš
éã§ãããããã«ç¬¬ïŒè¡šã«ç€ºãããã«è¢«æ€ç©è³ªã®
æäžãšäœå€è¡æ¶²åŸªç°ã®éå§ãŸã§ã®æéãããŸããŸ
ã«å€ããŠå®éšãè¡ãªã€ããçµæã第ïŒè¡šã«ç€ºãã
ããŒã¿ã¯åæéã§ããããæå¶çã§ç€ºããã
ãè¡šã
ãªããççé£å¡©æ°Žã®ã¿ãåŠçœ®ããåç©ãããªã
ã¡å¯Ÿç §çŸ€ã®è¡æ å¹³åééã¯92.98±5.69mgã§ãã€
ãã ïŒãã€ããªã³æº¶è§£æŽ»æ§ïŒ (1) ã©ããã«éèå æäžããã°ããã®F.D.P. å®éšã«ã¯å¹³åäœéçŽ220ïœã®éæ§ãŠã€ã¹ã¿ãŒç³»
ã©ãããçšããã被æ€ç©è³ªã¯ç¡éº»é ã®åç©ã«å± 殺
å30åã60åã120åããã³240åã®æç¹ã§éèå
æäžããã溶åªãšããŠèžæºæ°ŽãïŒmgïŒKgã®å²åã§
çšããããã€ããªã³å解çæç©ã¯Boehringer
MannheimïŒStaphylococcal Clumping Testã®ããããçšããŠè¡æŒ¿ãã調
ã¹ããå¯Ÿç §çŸ€ã®å€ã¯ççé£å¡©æ°ŽãïŒmgïŒKgã®å²å
ã§æäžããŠç®åºãããçµæã第ïŒè¡šã«ç€ºãã
ã¡å¯Ÿç §çŸ€ã®è¡æ å¹³åééã¯92.98±5.69mgã§ãã€
ãã ïŒãã€ããªã³æº¶è§£æŽ»æ§ïŒ (1) ã©ããã«éèå æäžããã°ããã®F.D.P. å®éšã«ã¯å¹³åäœéçŽ220ïœã®éæ§ãŠã€ã¹ã¿ãŒç³»
ã©ãããçšããã被æ€ç©è³ªã¯ç¡éº»é ã®åç©ã«å± 殺
å30åã60åã120åããã³240åã®æç¹ã§éèå
æäžããã溶åªãšããŠèžæºæ°ŽãïŒmgïŒKgã®å²åã§
çšããããã€ããªã³å解çæç©ã¯Boehringer
MannheimïŒStaphylococcal Clumping Testã®ããããçšããŠè¡æŒ¿ãã調
ã¹ããå¯Ÿç §çŸ€ã®å€ã¯ççé£å¡©æ°ŽãïŒmgïŒKgã®å²å
ã§æäžããŠç®åºãããçµæã第ïŒè¡šã«ç€ºãã
ãè¡šã
ã€ãã«ãªã€ã°ãããªã³ã®æº¶è§£ã«èŠããæéã調
ã¹ããå®éšæ¹æ³ã¯ä»¥äžã«ç€ºããšããã§ãããè¡æŒ¿
äžã®ãªã€ã°ãããªã³ç»åã¯ããã©ã¹ãããŒã²ã³ã¢
ã¯ãã€ããŒã¿ãŒããã©ã¹ãããŒã²ã³ãšãã€ããªã
ãŒã²ã³ãå«ãã§ããããªã€ã°ãããªã³ãå«ãã§ã
ãç»åã¯ããã³ãã³ã«ãã€ãŠååºãããã®ååºç©
ã®æº¶è§£ã«èŠããæéãGGMååšäžãŸãã¯éååš
äžã§ç®åºããããŠã€ã¹ã¿ãŒç³»ã©ããã®è¡æŒ¿ãçšã
ãŠGGMã®ïŒã€ã®çšéã«ã€ããŠEuglobulin Lysis
ReagentsâDade Diagnosticsãã¢ã°ã¢ã
ïŒAguadaïŒãããšã«ããªã³ã®ããããçšããŠèª¿ã¹
ããçšããGGMã®çšéã¯25ÎŒïœã50ÎŒïœããã³
100ÎŒïœãšãããçµæã第ïŒè¡šã«ç€ºãã
ã¹ããå®éšæ¹æ³ã¯ä»¥äžã«ç€ºããšããã§ãããè¡æŒ¿
äžã®ãªã€ã°ãããªã³ç»åã¯ããã©ã¹ãããŒã²ã³ã¢
ã¯ãã€ããŒã¿ãŒããã©ã¹ãããŒã²ã³ãšãã€ããªã
ãŒã²ã³ãå«ãã§ããããªã€ã°ãããªã³ãå«ãã§ã
ãç»åã¯ããã³ãã³ã«ãã€ãŠååºãããã®ååºç©
ã®æº¶è§£ã«èŠããæéãGGMååšäžãŸãã¯éååš
äžã§ç®åºããããŠã€ã¹ã¿ãŒç³»ã©ããã®è¡æŒ¿ãçšã
ãŠGGMã®ïŒã€ã®çšéã«ã€ããŠEuglobulin Lysis
ReagentsâDade Diagnosticsãã¢ã°ã¢ã
ïŒAguadaïŒãããšã«ããªã³ã®ããããçšããŠèª¿ã¹
ããçšããGGMã®çšéã¯25ÎŒïœã50ÎŒïœããã³
100ÎŒïœãšãããçµæã第ïŒè¡šã«ç€ºãã
ãè¡šã
ïŒããã§ã®è©ŠéšïŒ
ãªã€ã°ãããªã³æº¶è§£ã«èŠããæéã調ã¹ããå¥
康ãªãã©ã³ãã€ã¢ããã®ããè¡æŒ¿ãå®éšã«äŸã
ããå®éšã¯Euglobulin lysis ReagentâDade
Diagnosticsãã¢ã¯ã¢ãïŒAguadaïŒãããšã«ããª
ã³ã®ããããçšãããå ã®å®éšã§çšããGGMã®
25ÎŒïœã50ÎŒïœã100ÎŒïœã®çšéã«ã€ããŠèª¿ã¹ãã
çµæã第ïŒè¡šã«ç€ºãã
康ãªãã©ã³ãã€ã¢ããã®ããè¡æŒ¿ãå®éšã«äŸã
ããå®éšã¯Euglobulin lysis ReagentâDade
Diagnosticsãã¢ã¯ã¢ãïŒAguadaïŒãããšã«ããª
ã³ã®ããããçšãããå ã®å®éšã§çšããGGMã®
25ÎŒïœã50ÎŒïœã100ÎŒïœã®çšéã«ã€ããŠèª¿ã¹ãã
çµæã第ïŒè¡šã«ç€ºãã
ãè¡šã
æ¬çºæã¯ãã°ã«ã³ãµããã°ã«ã«ã³èªå°äœã®æè¡
æ å€ãšããŠã®äœ¿çšããšãã«ããäžå®éã®èšåºçã«
æå¹ãªã°ã«ã³ãµããã°ã«ã«ã³èªå°äœã®å°ãªããšã
ïŒçš®ãæå¹æåãšããããã«èª¿å€äžããçšããã
ã賊圢å€ãå«ã補å€ã«é¢ãããã¹ãŠã®å·¥æ¥ççšé
ã«é¢ãããã®ã§ããã補å€ã¯çèå ããã³éèå
泚å°å€ã湿åžå€ãé å€ãã«ãã»ã«å€ãªã©ã®å€åœ¢ã§
䜿çšãããã
æ å€ãšããŠã®äœ¿çšããšãã«ããäžå®éã®èšåºçã«
æå¹ãªã°ã«ã³ãµããã°ã«ã«ã³èªå°äœã®å°ãªããšã
ïŒçš®ãæå¹æåãšããããã«èª¿å€äžããçšããã
ã賊圢å€ãå«ã補å€ã«é¢ãããã¹ãŠã®å·¥æ¥ççšé
ã«é¢ãããã®ã§ããã補å€ã¯çèå ããã³éèå
泚å°å€ã湿åžå€ãé å€ãã«ãã»ã«å€ãªã©ã®å€åœ¢ã§
䜿çšãããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ïŒ®âè±ç¡«é žããã³ãµã¯ã·ãã«åããããšã«ã
ã€ãŠä¿®é£ŸãããŠãããããªã³ã®ãã©ã¯ã·ãšã³ã§ã
ã€ãŠã該ãã©ã¯ã·ãšã³ãâç¡«é žåºã修食åã®ã
ããªã³ã®10ïŒ æªæºå«ã¿ãã€äºç³åäœããã0.6ã
è¶ ãããµã¯ã·ãã«åºãå«ãã§ãããããªã³ãã©ã¯
ã·ãšã³ãæå¹æåãšããå¿èæ¢å¡ãè³æ¢å¡ããã³
éèè¡æ ã®äºé²ããã³æ²»çã«æçšãªæè¡æ å€ã ïŒ ä¿®é£Ÿããããããªã³ãäºç³åäœããããµã¯ã·
ãã«åºãçŽ1.2å«ãã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æè¡æ å€ã ïŒ éèå æäžãè žç®¡å€æäžãŸãã¯çµå£æäžçšã®
åäœè£œå€ã®åœ¢ã«è£œå€åãããŠãªãç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æè¡æ å€ã ïŒ åèšæå¹æåã0.5ã300mgïŒKgäœéå«æããŠ
ãªãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æè¡æ å€ã ïŒ åèšæå¹æåãïŒã30mgïŒKgäœéå«æããŠãª
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æè¡æ å€ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT23422A/83 | 1983-10-25 | ||
IT23422/83A IT1169888B (it) | 1983-10-25 | 1983-10-25 | Glicosaminoglicani modificati dotati di attivita' antitrombotica |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS60109524A JPS60109524A (ja) | 1985-06-15 |
JPS6357407B2 true JPS6357407B2 (ja) | 1988-11-11 |
Family
ID=11206953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59223825A Granted JPS60109524A (ja) | 1983-10-25 | 1984-10-24 | æè¡æ å€ |
Country Status (7)
Country | Link |
---|---|
US (1) | US4717719A (ja) |
JP (1) | JPS60109524A (ja) |
CH (1) | CH661439A5 (ja) |
DE (1) | DE3403256A1 (ja) |
DK (1) | DK508084A (ja) |
ES (1) | ES537393A0 (ja) |
IT (1) | IT1169888B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3422518A1 (de) * | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen |
US4840940A (en) * | 1987-10-21 | 1989-06-20 | Sottiurai Vikrom S | Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin |
DE3821271A1 (de) * | 1988-06-23 | 1989-12-28 | Solco Basel Ag | Derivatisiertes heparin, verfahren zu dessen herstellung und arzneimittel, welches dieses enthaelt |
AR245455A1 (es) * | 1989-08-18 | 1994-01-31 | Ajorca Sa | Procedimiento para la obtencion de derivados de heparina,parcial o totalmente n-acetilados en el resto glucosaminico y productos asi obtenidos excluidos sus usos farmaceuticos. |
WO1996001278A1 (fr) * | 1994-07-01 | 1996-01-18 | Seikagaku Corporation | Procede pour produire un polysaccharide desulfate et une heparine desulfatee |
GB0216861D0 (en) * | 2002-07-19 | 2002-08-28 | Univ Birmingham | Saccharide libraries |
JP5122436B2 (ja) * | 2006-03-14 | 2013-01-16 | åœç«å€§åŠæ³äºº å¥è¯å 端ç§åŠæè¡å€§åŠé¢å€§åŠ | æ°èŠãªãããªã³ä»£æ¿ææããã³ãã®è£œé æ¹æ³ |
US8383156B2 (en) * | 2007-04-30 | 2013-02-26 | Cordis Corporation | Coating for a medical device having an anti-thrombotic conjugate |
US8592393B2 (en) * | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
WO2009059284A2 (en) * | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
WO2011130697A2 (en) | 2010-04-16 | 2011-10-20 | Momenta Pharmaceuticals, Inc. | Tissue targeting |
US10017585B2 (en) | 2010-06-17 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
GB201219696D0 (en) | 2012-11-01 | 2012-12-12 | Univ Liverpool | Agents for the prevention and/or treatment of central nervous system damamge |
CA2910837A1 (en) | 2013-05-28 | 2014-12-04 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1201322B (de) * | 1958-07-05 | 1965-09-23 | Roussel Uclaf | Verfahren zur Herstellung von N-Acylderivaten des N-Desulfoheparins |
US3118816A (en) * | 1962-04-03 | 1964-01-21 | Abbott Lab | N-succinyl heparin and process |
IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
IT1140999B (it) * | 1980-06-18 | 1986-10-10 | Italfarmaco Spa | Glicosaminoglicani modificati dotati di attivita' antilipemica e privi di attivita' anticoagulante |
US4385046A (en) * | 1980-12-15 | 1983-05-24 | Minnesota Mining And Manufacturing Company | Diagnostic radio-labeled polysaccharide derivatives |
-
1983
- 1983-10-25 IT IT23422/83A patent/IT1169888B/it active
-
1984
- 1984-01-20 US US06/572,448 patent/US4717719A/en not_active Expired - Fee Related
- 1984-01-31 DE DE19843403256 patent/DE3403256A1/de active Granted
- 1984-10-19 CH CH5024/84A patent/CH661439A5/it not_active IP Right Cessation
- 1984-10-24 JP JP59223825A patent/JPS60109524A/ja active Granted
- 1984-10-24 DK DK508084A patent/DK508084A/da not_active Application Discontinuation
- 1984-10-24 ES ES537393A patent/ES537393A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
IT1169888B (it) | 1987-06-03 |
IT8323422A0 (it) | 1983-10-25 |
US4717719A (en) | 1988-01-05 |
JPS60109524A (ja) | 1985-06-15 |
DE3403256A1 (de) | 1985-05-02 |
DK508084A (da) | 1985-04-26 |
CH661439A5 (it) | 1987-07-31 |
ES8602041A1 (es) | 1985-11-16 |
ES537393A0 (es) | 1985-11-16 |
DE3403256C2 (ja) | 1990-10-31 |
DK508084D0 (da) | 1984-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Berry et al. | Antithrombotic actions of argatroban in rat models of venous,âmixedâand arterial thrombosis, and its effects on the tail transection bleeding time | |
JPS6357407B2 (ja) | ||
EP0497756B1 (en) | Antithrombotic composition | |
AU2897900A (en) | Antithrombotic use of glycine betaine | |
BG64542B1 (bg) | ЀÐÐ ÐÐЊÐÐТÐЧÐРСЪСТÐÐ, ÐÐÐЮЧÐÐЩ СЪÐÐÐÐÐÐÐÐ, ÐÐ ÐТÐÐÐÐÐЩРÐÐТÐ- Ð¥a ÐÐТÐÐÐÐСТ РСЪÐÐÐÐÐÐÐÐ-ÐÐТÐÐÐÐÐСТ ÐÐ ÐÐÐ ÐÐÐÐ ÐÐÐТРÐРТРÐÐÐÐЊÐТÐТР| |
JPH03243601A (ja) | è¡æ¶²ååºã®å¶åŸ¡èœããã€ã ã³å€ç³çµæç©ããã³ãã®è£œé æ¹æ³ | |
JP2003504428A (ja) | ã¯ãããé¢é£ååºå åãé»å®³ãããããªã³çµæç© | |
AU658594B2 (en) | Heparin derivatives | |
JP2002527479A (ja) | ããã©ãããã€ãœãããªã³ç³»ååç©ãå«æããè¬åŠççµæç© | |
MÃŒllerâBerghaus et al. | Production of the generalized Shwartzman reaction in rabbits by ancrod (âArvinâ) infusion and endotoxin injection | |
Valle et al. | Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis | |
Sabiston Jr | Pathophysiology, diagnosis, and management of pulmonary embolism | |
Thiagarajan | Antithrombotic Drugs | |
Duval et al. | Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin | |
RU2142799C1 (ru) | ТÑПЌбПлОÑОÑеÑкОе ÑÑеЎÑÑва | |
Koszewski et al. | Hypercoagulability syndrome due to heparin co-factor deficiency | |
Oguma et al. | Clinical effect of low molecular weight heparin (fragmin) on DIC: a multicenter cooperative study in Japan | |
Bogaty-Yver et al. | Thrombin-antithrombin III complexes for the detection of postoperative hypercoagulable state in surgical patients receiving heparin prophylaxis | |
Tremoli et al. | Studies on the antithrombotic action of Boc-D-Phe-Pro-Arg-H (GYKI 14,451) | |
WO2006047949A1 (en) | The use of human urinary kallidinogenase for the manufacture of a medicine for the treatment of acute coronary syndromes | |
EP0811377A1 (en) | Thrombolytic agent | |
JP4166851B2 (ja) | æ°èŠèè¡ã»åçæµé害æå¶å€ | |
Verstraete et al. | Drugs affecting blood coagulation and hemostasis | |
CN115093457A (zh) | äžç§æåè¡å€èœkt12åå ¶åºçš | |
Tremoli et al. | Gyki 14,451, a Synthetic Tripeptide Inhibitor of Thrombin:âIn Vitroâ and âIn Vivoâ Studies |